Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHERFLOT
2021-006512-87Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, trastuzumab, oxaliplatin, folinic acid, fluorouracil and 1 more in gastroesophageal junction adenocarcinoma and esophagogastric junction cancer, sponsored by Institut für Klinische Krebsforschung. Primary endpoints: Disease-free survival and Pathological complete response rate. Started Jul 2022; status: active.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomaesophagogastric junction cancer
Beyond the preview
Go deeper on 2021-006512-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006512-87.